Introduction
Epilepsy imposes significant financial costs on individuals, families and the health care services supporting them. As a consequence, an understanding of the costs of epilepsy and the factors influencing those costs is important for the efficient delivery of care for people with epilepsy. 1 Whilst a number of studies have examined costs of epilepsy in regions around the world, [2] [3] [4] [5] [6] patients with significant intellectual disability (ID) (defined as an IQ of 70 or less) are often excluded. In addition, psychiatric co-morbidities, which occur at increased rates in those with ID 7 and social support costs for people with epilepsy and ID are rarely considered in detail. Nevertheless, ID is relatively common in people with epilepsy, probably occurring in at least 25%. 8, 9 Similarly, epilepsy is common in adults with ID, 10 with an overall prevalence of around 26%.
11
Epilepsy in adults with ID has a worse prognosis than epilepsy in the general population, with lower rates of seizure freedom, 9 high rates of multiple antiepileptic drug use, 12 and high rates of comorbidity 13 and mortality. 14 All these factors are likely to have important financial implications. Hence adults with ID represent a distinct and sizeable proportion of those with epilepsy and one for which costs associated with delivery of epilepsy care remains underresearched. Our aim in this paper is to report the health and social care costs of supporting adults with active epilepsy and ID living in the community in the UK and to explore determinants of those costs.
Methods

Study design
This was a prospective study designed to collect data describing, over seven months, epilepsy; ID; quality of life; and health and social care utilisation for a group of adults with ID and epilepsy living in the east of England.
Entry into the study and collection of relevant background data took place during an initial recruitment visit. Participants then underwent four subsequent assessments at one, two, six and seven months. The study aimed to interview the same family member or paid carer on each occasion, as well as, where feasible, the participant. Assessments were carried out in participants' homes or at the site of day activities in which they were engaged.
Results: Mean health care costs relating to epilepsy or ID were £2800 (3500 Euros, 5200 USD) p.a.
Modelling suggests costs are lower for patients with more severe ID (p = 0.014); and higher for patients managed by a consultant neurologist (p = 0.037). Discussion: Our findings support limited evidence from the literature of increased epilepsy costs in people with ID. Patterns of expenditure suggest clinical variation in the treatment of epilepsy according to the severity of ID, particularly in the absence of management by a consultant neurologist.
ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Participant recruitment
In the UK, epilepsy care for adults with ID is generally provided by some combination of hospital neurology or community ID health services and primary care. Community ID teams generally include nurses and psychiatrists with expertise in the management of epilepsy, and provide services to all adults with an IQ of 70 or less aged 18-65 years. The areas in our study were also within the catchment of teaching hospitals which included neurologists with a special interest in epilepsy and epilepsy specialist nurses. We sought to recruit 100 adults with ID and active epilepsy whose epilepsy was managed by a community ID team and 100 whose epilepsy was managed by a hospital neurology service. These numbers would have been sufficient to detect a difference of 3 points on the National Seizure Severity Scale with 96% power (p = 0.05), based on data from a pilot study in Cambridgeshire.
Eligible participants comprised all adults aged between 18 and 65 years with epilepsy and a record of at least one seizure, not considered to have been non-epileptic, in the six months preceding the study, with a full scale IQ below 71, living in Cambridgeshire or Norfolk and known to community ID and/or hospital neurology services in these counties.
Potentially eligible participants were initially identified by the clinicians providing their ongoing epilepsy management. All potential participants identified (334) were contacted. Of the 198 responses, 28 were ineligible. The remaining participants were included in the study provided consent was obtained from those able to give consent or, in the case of those lacking capacity to consent, assent was obtained from a carer under the provisions of the Mental Capacity Act (UK) (2005). The study was approved by the Cambridgeshire 2 Research Ethics Committee.
Assessments
At the initial recruitment visit the following information was collected; clinical details describing severity of ID, the nature of the epilepsy and its treatment, the prevalence of associated neurological and psychopathological comorbidities, accommodation and demographic information including ethnic origin.
At each of the four subsequent data gathering visits the following assessments were undertaken (unless frequency is otherwise specified); the abbreviated Glasgow Epilepsy Outcome Scale 35 (GEOS35) 15 (completed at first and fourth visits only);
Epilepsy and Learning Disabilities Quality of Life Scale (ELD-QOL); 16, 17 seizure severity, measured using the seizure severity scale section of the ELDQOL; Glasgow Depression Scale for people with a Learning Disability (GDS-LD) 18 or the Carer Supplement to the scale (GDS-CS) for those unable to complete the GDS-LD themselves; EuroQoL (EQ-5D); 19 and a modified version of the Client Service Receipt Inventory (CSRI). 20 In addition, the primary carer completed a seizure diary for each participant covering the seven months of their involvement in the study. Members of the research team advised carers on how to complete the diary accurately using a protocol and reviewed it at each visit over the data collection period, with additional phone calls between visits to support reliable recording. Clinical details were gathered from carers and from examination of participants' clinical records by members of the research team. The GEOS35 is a shortened version of the 90 item GEOS90 carer report. 15 Both measures have four subscales measuring carer ''concerns about seizures'', ''medical treatment'', ''caring'' and ''social impact''. The ELDQOL is a 70 item measure covering seizure severity, seizure related injury, antiepileptic drug (AED) side effects, behaviour, mood, physical, cognitive and social functioning, communication, overall health and quality of life and family concerns. The EQ-5D comprises two generic measures of health status: the 'tariff' is derived from assessment of functioning in mobility, self-care, social functioning, pain and mood; the Visual Analogue Scale (VAS) score is a simple scale of overall health from zero to 100 (best imaginable health). The ELDQOL, EQ5D and GEOS35 instruments were scored according to published protocols. Missing data was imputed according to scoring protocols, provided sufficient questions had been completed. The EQ5D tariff scores were based on the UK general population values, 21 which generates scores from minus 0.594 to one (where one is equivalent to full health; zero represents death; and scores below zero represent health states rated worse than death).
Measurement of costs
The study took a societal perspective and attempted to capture all health and social care input relating to epilepsy and ID including primary care; inpatient and outpatient care; drug prescriptions; home adaptations; and support groups and activities for people with ID. This included valuation of the contribution of family carers. We modified the CSRI to make it relevant to people with epilepsy and ID and to record service use for the previous month only. The main modifications were undertaken to collect detailed data on social care provision, medications and activities relevant to people with an ID. (The modified questionnaire is available at http://www.ciddrg.org.uk/ldrome/.) The questionnaire recorded the location of activities and contacts with professionals and the mode of transport for participants where appropriate. Approximate contact times were recorded. Contact times were combined with appropriate unit costs (visiting or at place of work) for professionals and travel costs were added. Unit costs were taken predominantly from the Unit Costs of Health and Social Care 22 and all costs are in 2008 UK pounds sterling. Outpatient visits were split into three categories; ID psychiatry, neurology and other. Inpatient visits were categorised as ID psychiatry, neurology, specialty-specific or general medical (long stay) and a cost was assigned per day. Drug costs were calculated from detailed data on brand, dose and frequency combined with appropriate costs from the British National Formulary. Valuing time spent by carers is contentious. 24, 25 We applied a unit cost equivalent to the average gross hourly wage by category of employment for hours spent caring by working carers as recommended by Gold et al. 26 We applied a value of £7 per hour for non-working carers, based on the mean unskilled gross wage rate.
To avoid overestimating care costs we classified caring duties into four categories: hours directly giving care; hours of leisure activity; hours supervising; available but sleeping. Hours in each of the categories were weighted 1, 0.5, 0.2 and 0.1 respectively. The weights were chosen to reflect the likely burden of different caring activities. Private sector care providers were reluctant to reveal accommodation and placement costs, hence we categorised participants' placements as residential care; supported living for people with ID; group homes; or village communities and applied appropriate unit costs. 22 Few cost studies in the literature have utilised a control to ascertain costs attributable to epilepsy. 27 Most include all costs falling into categories whose most likely cause is epilepsy, 3, 28, 29 and this was the approach we used for health care costs. Costs for social care were assumed to be entirely attributable to the combination of ID and epilepsy. Cost data were divided into five broad categories to facilitate comparison with other studies: accommodation costs; social activities; primary health and community support (including aids and adaptations in the home); drug costs (relating to epilepsy or ID); and secondary health care (relating to epilepsy or ID). Primary health and social support consisted mainly of health care interventions but included support by social workers and case management meetings. Home help to assist with caring tasks was included in accommodation, as was the estimated cost of informal care. Secondary health care included inpatient visits; outpatient visits; and any hospital based tests or investigations related to epilepsy or ID.
Data analysis
For each participant, mean values were derived for costs and outcomes measured over multiple time periods. Overall costs were dominated by accommodation costs. As highlighted earlier our ability to accurately estimate accommodation costs was limited, and the tariffs we applied were unlikely to reflect the subtle influences of participants' quality of life or epilepsy severity. Consequently exploration of the impact of patient characteristics and care pathways on costs was restricted to costs determined predominantly by the participant's epilepsy: drug use, and primary and secondary healthcare. We pre-specified the inclusion of five key variables: age, gender, a measure of ID severity, a measure of seizure severity, and the assignment of clinician responsible for epilepsy management. Additional variables were evaluated according to their significance in explaining variability in the cost data.
The sum of epilepsy related health care costs for each participant was right skewed as is commonly observed for cost data. 30 Generalised Linear Models (GLM) are preferred for modelling cost data as they provide increased flexibility in the choice of distribution; Gamma distributions generally fit cost data better than Normal distributions. 31 However, there are concerns over the potential robustness of fitting GLM models to small data sets. Tests of specification will be underpowered in a small sample, and misspecification can result in biased estimates of effect. Consequently we fitted a GLM and an ordinary least squares (OLS) model to the data. The GLM model was optimised using appropriate specification tests. [32] [33] [34] The same variables were examined using an OLS regression with robust standard errors.
Results
Raw data
We gained consent and collected data on a total of 91 participants. For four participants data were available at less than four time points. Table 1 presents demographic characteristics describing the participants and mean scores for the ELDQOL, GEOS35, and EQ5D. Two participants were non-white, reflecting the ethnic composition of Norfolk and Cambridgeshire. Data was missing on the number of seizure types and age at onset of epilepsy for some of the participants. The majority of participants lived in local authority provided group homes or residential settings rather than with family members. Seven participants lived independently. Slightly over half the participants had severe or profound ID (IQ of 35 or less). Most participants had epilepsy since childhood and the majority were being prescribed more than one AED. Across the study population the median number of convulsive seizures per month was 0.7 (range 0-91) and the median number of nonconvulsive seizures per month was 0.6 (range 0-135). Health Related Quality of Life (HRQoL) measured by the EQ5D tariff was significantly lower than UK norms (0.85 for UK adults);
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VAS scores were also depressed but less strongly. Table 2 presents the raw monthly cost data. Cost data were unavailable for one participant. Accommodation costs are the largest contributor with overall mean costs of just over £4000
(5000 Euros, 7400 USD) a month. The next most significant cost category is Activities. This category included day centres and social clubs as well as individual interventions such as aromatherapy. These costs relate predominantly to participants' ID although epilepsy is likely to impact on the cost of providing safe accommodation and activities. The remaining categories (community services, hospital services and drug costs) are primarily health care related to epilepsy. These costs are relatively small; the mean aggregate costs for hospital care, community care and drugs is £232 (291 Euros, 429 USD) a month. A latent class model was used to categorise participants according to the clinician responsible for their epilepsy management based on case note entries and the opinions of primary care physicians and carers. Forty-two participants were determined to have their epilepsy primarily managed by a psychiatrist in an ID team; 36 participants by a neurologist; and 11 participants by a General Practitioner or by a combination of professionals. We were unable to assign the management team responsible for epilepsy care in one participant. Analysis of the raw data revealed that the mean number of seizure types was 2.06 for participants managed by a neurologist compared to 1.72 for participants managed by their ID team and 1.8 for participants managed by their GP. The prevalence of severe or profound ID was 47% in those managed by a neurologist compared to 68% in the remaining sample. These differences were not statistically significant at 5%. Table 3 provides a breakdown of monthly costs arising predominantly from epilepsy according to clinician managing the participant's care.
Analysis of costs
A GLM model of the costs arising primarily from epilepsy was fitted using a Gamma distribution with a log link for the explanatory variables. Of the ELDQOL, GEOS-35 and EQ5D measures of participants' quality of life, the GEOS-35 'concerns about seizures' subscale and the EQ5D VAS score proved to be the best predictors of variation in costs. Initial analysis indicated similar costs for participants with profound ID and those with severe ID. In addition the magnitude of cost differences between Total   £5304  £5576  £2548  £1593  £10,114 mild, moderate and severe ID were each similar. Consequently ID severity was treated as a numerical variable with values one to three for levels mild/moderate/severe (profound) respectively. We had a number of indices of seizure severity including the Seizure Severity subscale of the ELDQOL, the mean number of seizures per month and the number of different types of seizures. The latter measure proved to be the most significant predictor of costs. The presence or history of neurological or affective comorbidities, and the duration of epilepsy were not significant predictors of cost.
Neither was the use of rescue medication, but the number of AEDS prescribed was. Geographic location also proved to be significantly related to costs. Initial multivariate analysis showed a significant difference between costs for patients managed by a neurologist and patients managed by their GP (p = 0.036) but no significant difference between costs for patients managed by their ID team or their GP (p = 0.413). Consequently we combined the groups managed by an LD team or a GP. The interaction of epilepsy clinician and ID severity was the only significant interaction term. After optimising the GLM model we fitted an OLS model to the same explanatory variables. The models are described in Table 4 . Akaike's Information Criteria, 36 a measure of model fit, indicated the GLM model was superior. The method of recycled predictions 37 was used to estimate cost differences for epilepsy-related care according to a number of characteristics including neurologist management of epilepsy and ID severity for both the GLM and OLS models. In this method the entire sample is assigned a specific value for a variable of interest, outcomes are estimated, and then compared with outcomes arising if the entire sample is assigned the comparator value for the variable of interest. Predictions from both models were similar (Table 5) . Bootstrapped 95% confidence intervals are presented for cost differences generated in the GLM model. A reduction in quality of life as indicated by a change from the upper end to the lower end of the IQR for either the GEOS35 subscale 'concerns about seizures' or the EQ5D VAS scale leads to a significant increase in costs. Costs are significantly lower for participants with severe or profound ID compared to those with mild ID. Costs are significantly higher ; link function: g(u) = ln(u). £60  £0  £110  £18  £21  £0  £75  £0   Community services   £99  £71  £34  £8  £77  £51  £70  £36   Drugs   £75  £54  £113  £111  £41  £29  £86  £63   Total   £234  £124  £257  £138  £139  £80 £232 £99 when a neurologist coordinates care. There is far less variation in costs according to ID severity where patients are managed by a neurologist due to the strong interaction between ID severity and neurologist.
Discussion
The high health and social care costs of supporting people with epilepsy and ID and the significant prevalence of ID amongst people with epilepsy indicate that people with ID constitute a large proportion of health and social care expenditure incurred by people with epilepsy. Despite this few studies have focussed primarily or exclusively on the cost of supporting people with epilepsy and ID. [38] [39] [40] Our study estimates the total cost to be around £64,000 (80,000 Euros, 118,000 USD) a year (2008 values).
Three quarters of that expenditure is spent supporting the accommodation and basic care needs of people with epilepsy and ID, and a further fifth on day centres, support groups and activities. Costs falling on social care budgets are far higher than health care costs.
Our findings accord with a study of people with severe or profound ID in a US institution which reported overall annual costs of 100,000 1997 dollars. 38 The additional costs of epilepsy, excluding treatment provided outside the institution, were estimated at $2000. Both Morgan et al. 39 after inflation to 2008 values, indicating epilepsy treatment is more resource intensive in the presence of ID. We observed higher costs in patients whose care is coordinated by a neurologist after controlling for the number of seizure types a participant had and the number of AEDs prescribed (Table 3) . This finding may be attributable to unobserved differences in patient characteristics. However, treatment of refractory epilepsy involves finding a balance between exhausting therapeutic options and providing some stability and predictability for the patient and their family/carers. 13, 41 Achieving the best outcome for the individual requires compromise, with both patient and clinician involved in a joint process of treatment negotiation and decision-making. 41 It is possible that neurologists are more active in pursuing seizure control; and that ID teams place a higher emphasis on stability and avoidance of adverse treatment effects. This may also explain the observed negative relationship between ID severity and costs; a relationship primarily noted in participants not managed by a neurologist. It is plausible that clinical management of epilepsy was pursued less aggressively in patients with severe and profound ID not under the care of Neurologists, with the resulting effect of reducing epilepsy costs. Whilst this variation may be appropriate, future research investigating the nature and cost-effectiveness of epilepsy care pathways for adults with ID and epilepsy is warranted.
The use of the EQ5D in people with restricted ability to complete questionnaires unaided is limited. 42 However, the very significant coefficient on the EQ5D VAS score in our cost models suggests that this measure is informative in this group. The GEOS-35 Carer 'concern about seizures' subscale was also more strongly correlated with costs than more objective measures of epilepsy severity, such as the ELDQOL seizure severity subscale score or the mean monthly number of seizures, suggesting that future research should further explore relationships between carer concerns and interactions with health services. Considering the representativeness of the study sample, overall the group had a mean duration of epilepsy of 31 years, and 70% were taking more than one antiepileptic drug. A previous survey 12 of adults with ID and epilepsy in the same region of England observed mean duration of epilepsy of 26 years and a monotherapy rate of 39%, whilst a postal survey of a different region in England noted 48% receiving antiepileptic drug monotherapy. 43 Hence the study population reported here may have rather more severe epilepsy than the wider population of adults with ID. This may have resulted from the eligibility criteria for the study which required evidence of an epileptic seizure within the preceding six months. Similarly, although mean number of seizure types was higher in the neurology than the non-neurology group, despite the neurology group having a smaller number of severe and profound ID cases, this difference was non-significant and the study's focus on people with active epilepsy is likely to have included individuals across all IQ bands with more refractory epilepsy, associated with a larger number of seizure types. In addition, compared to the wider population of adults with ID, the participants of this study were more likely to have severe or profound ID and to be living in group homes. 44 Clearly the study has a number of limitations. Failure to recruit the target sample of 200 participants reduced the power of the study. We had a power of 88% to detect differences in GEOS score of 11 between participants managed by neurology and ID teams (equivalent to the typical difference in GEOS score for somebody on antiepileptic drug monotherapy compared to polytherapy). Whilst data describing participants' neurological and psychological disorders were collected we did not collect data on characteristics such as incontinence and challenging behaviour not considered to be directly linked to the participant's epilepsy. However, it is likely that these characteristics would have influenced health care costs. The significant influence of geographic location of care on costs suggests variation in practice between Cambridgeshire and Norfolk, two similar, adjoining counties, potentially limiting the wider generalisability of our findings to other regions. At the same time however, the finding of a geographic effect on costs should be of interest in itself to those planning services.
The sample achieved necessitated simplifications in the modelling of the cost data. Ideally multiple observations on cost and outcome should be recognised within the model rather than simply modelling the mean values. In addition, the correlations between participants in the same county ought to be recognised in a hierarchical model. We judged the impact of ignoring these issues to be small given the significant risks of unobserved baseline differences. We also chose to ignore the distinction between participants managed by their ID team and the small number managed primarily by their GP given the small sample and the indication that costs were not significantly different. Inferences drawn from differences in resource use across the participants in this study must also be tempered by the fact that this was an observational study. We cannot rule out the possibility that differences in resource use according to characteristics that appear significant in the model have arisen from a combination of chance and confounding by unobserved characteristics.
Conclusion
Costs on health and social services of supporting people with epilepsy and ID are high, primarily due to the cost of providing appropriate accommodation and living support along with appropriate activities for people with ID. Epilepsy related health care costs are a small fraction of overall costs. However, this study suggests that the costs of epilepsy management are higher for people with ID than for the rest of the population. Whilst affective and neurological comorbidities are relatively common in this clinical group, they were not found to contribute to differences in cost estimates for epilepsy related care. The results of the study do suggest that a significant determinant of epilepsy health care utilisation, as reflected in financial costs accrued, is a perception by carers of a worse health state in the person they are caring for. The unexpected finding of relatively lower epilepsy related costs in those with severe and profound ID could relate to less intensive epilepsy management in these groups, and this together with the apparent differential financial consequences of receiving treatment from neurology as opposed to ID or primary care services requires further investigation.
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